Mechanism by which newly approved melanoma drug accelerates secondary skin cancers uncovered

Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf®) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer. Now, researchers have elucidated the mechanism by which vemurafenib excels at fighting melanoma but also allows for the development of skin squamous cell carcinomas.

Read the whole article on Science Daily

More from Science Daily